May 24 (Reuters) - Indian generic drugmaker Emcure Pharmaceuticals (EMCU.NS), opens new tab and U.S. vaccine developer HDT Bio have settled allegations that Emcure stole HDT trade secrets during their ...

Pune-headquartered Emcure Pharmaceuticals plans to expand its gynaecology and dermatology product portfolio for the Indian market in FY26, the company’s top executive said on Thursday. “In women’s ...

Emcure Pharmaceuticals IPO aimed to raise ₹1,952.03 crore. The IPO, which opened for subscription on July 3, 2024, and closed on July 5, 2024, consisted of a fresh issue of 0.79 crore shares ...

Emcure Pharmaceuticals on Wednesday posted a 48 per cent year-on-year increase in its consolidated profit after tax at ₹231 crore for the third quarter ended December 31, 2025, led by robust sales ...